Phase 2 Vasculitis Trial, Recruiting NCT07089121 Sponsor: Cartesian Therapeutics Condition: Vasculitis
Back to Vasculitis

Phase 2 Vasculitis Trial, Recruiting

NCT07089121
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 12 years old
  • You have been officially diagnosed with one of the following conditions: childhood-onset lupus (systemic lupus erythematosus), juvenile Myasthenia gravis, juvenile dermatomyositis, or AAV (confirm with trial site for full name)
  • Your condition is considered moderately active, meaning you have noticeable signs and symptoms
  • You have previously received treatment that affected your whole body (not just a local treatment) for your condition
  • You (or your parent or guardian, if under 18) are able and willing to sign a written consent form to take part

Who may not be able to join:

  • You have a serious long-term illness that is not well controlled right now and could make the trial risky for you, in the doctor's opinion
  • Your blood clotting test results are significantly abnormal, or you are taking blood-thinning medication — though some exceptions may apply (confirm with trial site)
  • Your white blood cell count (a type called neutrophils) is too low
  • Your red blood cell level (haemoglobin) is below a certain point, suggesting significant anaemia
  • Your platelet count (cells that help blood clot) is too low — though platelet transfusions may be allowed
  • Your liver enzyme levels are too high (specifically ALT, AST, and GGT together)
  • Your kidneys are not working well enough (filtering too slowly)
  • You have a history of a primary immune system disorder, or you have had an organ transplant or bone marrow transplant from a donor
  • You have tested positive for hepatitis B
  • You have tested positive for hepatitis C and also have the virus actively present in your blood
  • You have HIV, or test positive for HIV at the start of the study
  • You have active tuberculosis (TB), or test positive for a TB screening test at the start of the study
  • You have any other abnormal lab results that the doctor feels could make it unsafe for you to participate
  • You have a significant heart or lung condition unrelated to your main diagnosis — though people with well-controlled asthma or COPD using inhalers may still be eligible
  • You have had a blood clot in an artery or vein in the past 3 months
  • You have been treated for cancer in the past 3 years — with some exceptions for certain skin or bowel cancers that were fully removed (confirm with trial site)
  • You have taken part in another clinical trial or used an experimental drug within the past 4 weeks (or longer, depending on the drug)
  • You have received a live vaccine within 4 weeks before the trial starts, or plan to receive one during the trial — note that mRNA COVID-19 vaccines are not considered live vaccines
  • You have a history of frequent or serious infections, or have an active infection right now
  • You have a known psychiatric (mental health) condition that, in the doctor's opinion, could affect your ability to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-231-8102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cartesian Therapeutics
Registry
ClinicalTrials.gov
Start date
14 January 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2; Maximum Dose Tolerated

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov